Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Holding(s) in Company | 26 Aug 2025 |
| Holding(s) in Company | 21 Aug 2025 |
| Director/PDMR Shareholding | 18 Aug 2025 |
| Holding(s) in Company | 15 Aug 2025 |
| Holding(s) in Company | 12 Aug 2025 |
| Total Voting Rights | 1 Aug 2025 |
| H1 and Q2 2025 results | 29 Jul 2025 |
| Gefurulimab nanobody met Phase III endpoints | 24 Jul 2025 |
| AstraZeneca plans to invest $50bn in the US | 22 Jul 2025 |
| Update on anselamimab in AL amyloidosis | 16 Jul 2025 |
| Baxdrostat met primary endpt in BaxHTN PhIII trial | 14 Jul 2025 |
| Imfinzi approved in the EU for bladder cancer | 4 Jul 2025 |